Eating Disorders Clinical Trial
Official title:
Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders
Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).
The investigators will use a randomized, placebo-controlled, double-blind, crossover trial to evaluate the use of fMRI as a pharmacodynamic biomarker of reward system modulation. The overall goal of this work is to develop an objective tool to detect acute drug response. If validated in future, larger trials, the pharmacodynamic biomarker may facilitate early phase/quantitative pharmacology studies of novel or repurposed agents expected to modulate the reward system. The reward system will be antagonized by naltrexone in adolescents aged 13-21 years with an ED defined by binge/purge behaviors (e.g., Anorexia Nervosa-Binge Purge, Bulimia Nervosa, Binge Eating Disorder). A crossover design was chosen to quantify within-individual change in opioid reward pathway modulation following antagonism. Eligible patients will be randomly assigned to Group A or Group B. A statistician (or other non-study staff) will generate the schedule and communicate with the investigation drug service to maintain the double-blind design. A washout period of at least 14 days will exceed the 48-hour carry-over effect from naltrexone 50 mg administered orally. The two study visits will be mirrored in structure and duration to maintain blinding. It is not the intent of this study to generate data for submission to the FDA or to support a significant change in advertising of the drug. Storage, control and dispensation of the drug will occur through collaboration with the investigational drug service (IDS) pharmacy. Use of naltrexone for this study meets criteria for investigational new drug (IND) exemption, category #1 (21 Code of Federal Regulations (CFR) 312.2(b)(1)). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05656859 -
Prevalence of Eating Disorders Among Patients in the Department of Health Promotion
|
||
Completed |
NCT04085861 -
Mental Health in Dancers; an Intervention Study
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Enrolling by invitation |
NCT04174703 -
Preparing for Eating Disorders Treatment Through Compassionate Letter-Writing
|
N/A | |
Terminated |
NCT04278755 -
Binge Eating & Birth Control
|
Phase 2 | |
Withdrawn |
NCT03050632 -
Effects of Cognitive and Emotional Functioning on Treatment Outcomes
|
N/A | |
Completed |
NCT02567890 -
Swedish Body Project for Prevention of Eating Disorders
|
N/A | |
Completed |
NCT02484794 -
Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application
|
N/A | |
Completed |
NCT02252822 -
Improving Treatment Engagement for Adolescents With Bulimia Nervosa
|
N/A | |
Completed |
NCT02021344 -
Mental Health First Aid for College Students
|
N/A | |
Completed |
NCT00601354 -
Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
|
N/A | |
Completed |
NCT00418977 -
Comparing the Effectiveness of Two Therapies to Treat Signs of Anorexia Nervosa in Adolescents
|
N/A | |
Completed |
NCT00304187 -
Effectiveness of Antibiotic Treatment for Reducing Binge Eating and Improving Digestive Function in Bulimia Nervosa
|
Phase 2 | |
Completed |
NCT00733525 -
Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa
|
N/A | |
Active, not recruiting |
NCT04779216 -
Effects of Romosozumab on Bone Density in Women With Anorexia Nervosa
|
Phase 3 | |
Completed |
NCT04433663 -
Eating Disorders, Self Regulation and Mentalization
|
N/A | |
Completed |
NCT04509531 -
Building Resilience in Cyberbullying Victims
|
N/A | |
Recruiting |
NCT05730348 -
Mealtime Anxiety in Eating Disorders
|
||
Enrolling by invitation |
NCT05814653 -
A Study to Evaluate Primary Care Treatment for Adolescent Eating Disorders
|
N/A | |
Completed |
NCT04506216 -
Eating Disorders in Type 1 Insulin-dependent Diabetes Patients
|
N/A |